Eltrombopag with Immunosuppressive Therapy Shows Promising Safety in Pediatric Severe Aplastic Anemia – Phase 2 ESCALATE Trial Results
Blood Journals Portfolio shared a post on X:
“Eltrombopag’s pharmacokinetics profile was similar to that seen in patients with immune thrombocytopenia, with no unexpected safety signals.”
Title: Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial
Authors: Akiko Shimamura, Alexey Maschan, Carolyn Bennett, Sujith Samarasinghe, Jason E. Farrar, Chi-kong Li, Nongnuch Sirachainan, Bunchoo Pongtanakul, Patcharee Komvilaisak, Ludmila Zubarovskaya, Jennifer A. Rothman, Kelly Walkovich, Taizo A. Nakano, Alison A. Bertuch, Anabela Ferrao, Rukhmi Bhat, Rabi Hanna, Kathleen Overholt, Jessica Boklan, Tze Fang Wong, Qinxia Wang, Patrick Urban, Brigitte Strahm, Winfred Wang, Adrianna Vlachos, David A. Williams
Read the full article here.
All the latest news featured in Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda